Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 15, 2020 | Director, Chairman & CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 22,000 | $23.91 | 823,513 | |
| Dec 15, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 22,000 | -- | 108,557 | |
| Jul 08, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 22,052 | $12.28 | 227,314 | |
| Jul 08, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 22,052 | -- | 17,896 | |
| Mar 14, 2014 | Sr Vice President Discovery | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Form 4 | 22,065 | $2.26 | 994,604 | |
| Jan 15, 2020 | Chief Legal Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 22,100 | $10.35 | 185,350 | |
| Jan 03, 2023 | Director, Executive Chairman | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 22,116 | $11.93 | 747,742 | |
| Oct 13, 2017 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4/A | 22,160 | $14.75 | 350,161 | |
| Oct 13, 2017 | Director, Chairman & CEO | Open market or private sale of non-derivative or derivative security | Form 4/A | 22,160 | $14.75 | 328,001 | |
| Oct 13, 2017 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4/A | 22,160 | -- | 139,378 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.